• Product Name:Tofacitinib Citrate
  • Molecular Formula:C16H20N6O·C6H8O7
  • Purity:99%
  • Molecular Weight:504.50

Product Details:

CasNo: 540737-29-9

Molecular Formula: C16H20N6O·C6H8O7

Quality Factory Supply Tofacitinib Citrate,Sale 540737-29-9 Fast Delivery

  • Molecular Formula:C16H20N6O·C6H8O7
  • Molecular Weight:504.50
  • Melting Point:201 °C (decomp) 
  • Boiling Point:585.8 °C at 760 mmHg 
  • Flash Point:308.1 °C 
  • PSA:221.04000 
  • LogP:0.23418 

Tofacitinib citrate(Cas 540737-29-9) Usage


Tofacitinib Citrate is the citrate salt obtained by combining equimolar amounts of tofacitinib, a Janus kinase (JAK) inhibitor, and citric acid. Tofacitinib is available in pill form, taken either as 5 mg twice a day (Xeljanz) or as 11 mg once per day (Xeljanz XR). It acts as a potent inhibitor of the JAK pathway, which plays a crucial role in the inflammatory response.

Chemical Structure

Tofacitinib citrate is a potent inhibitor of Janus kinase 3 (JAK3) with some JAK-1 inhibitory activity.


The brand name for Tofacitinib Citrate is XELJANZ. It was the first FDA-approved pill of its kind, belonging to the class of JAK inhibitors, for the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, and moderate to severe ulcerative colitis in adults. XELJANZ is available in various formulations, including immediate-release and extended-release tablets, to accommodate different dosing regimens and patient preferences.


ChEBI: A citrate salt obtained by combining equimolar amounts of tofacitinib and citric acid. Used to treat moderately to severely active Rheumatoid Arthritis.


540737-29-9 Relevant articles

Development of a robust, environmentally responsible process for the manufacture of tofacitinib citrate

R Vaidyanathan

Scalable Green Chemistry: Case Studies from the Pharmaceutical Industry

Process development efforts that resulted in a robust, environmentally responsible, commercializable process for tofacitinib citrate will be presented in this chapter.

Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata

Milène Kennedy Crispin,1 Justin M. Ko,1 Brittany G. Craiglow,2,3 Shufeng Li,1 Gautam Shankar,1 Jennifer R. Urban,4 James C. Chen,5,6 Jane E. Cerise,5 Ali Jabbari,5 Mårten C.G. Winge,1 M. Peter Marinkovich,1 Angela M. Christiano,5,7 Anthony E. Oro,1 and Brett A. King2

, JCI Insight. 2016 Sep 22; 1(15): e89776.

This was a 2-center, open-label, single-arm trial using the pan-JAK inhibitor, tofacitinib citrate, for AA with >50% scalp hair loss, alopecia totalis (AT), and alopecia universalis (AU). Tofacitinib (5 mg) was given twice daily for 3 months. Endpoints included regrowth of scalp hair, as assessed by the severity of alopecia tool (SALT), duration of hair growth after completion of therapy, and disease transcriptome.

Tofacitinib (Xeljanz): The First-in-Class JAK Inhibitor for the Treatment of Rheumatoid Arthritis

Robert W. Dugger, Mark E. Flanagan, Rajappa Vaidyanathan

Innovative Drug Synthesis, 16 November 2015

Tofacitinib operates by inhibiting the JAK pathways utilized by several cytokines implicated in the pathogenesis of the disease. The SAR associated with the tofacitinib discovery program has been reported on extensively. Key elements of this medicinal chemistry program include the application of high-throughput-screening (HTS) to identify a lead molecule (5); and the early use of high-speed analoging (HSA).

540737-29-9 Upstream products

  • 384336-73-6


  • 56657-76-2

    succinimidyl cyanoacetate

  • 77-92-9

    citric acid

  • 477600-74-1

    tert-butyl (3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate

Relevant Products